Polymorphism of rs1799782 (c.580C>T) is associated with outcome of NSCLC patients treated with platinum-based chemotherapy: a system review and meta-analysis

Background. There is no definitive conclusion so far on the predictive values of ERCC1 polymorphisms for clinical outcomes of platinum-based chemotherapy in non-small cell lung cancer (NSCLC). We updated this meta-analysis with an expectation to obtain some statistical advancement on this issue.Methods. Relevant studies were identified by searching MEDLINE, EMBASE databases from inception to April 2015. Primary outcomes included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). All analyses were performed using the Review Manager version 5.3 and the Stata version 12.0.Results. A total of 33 studies including 5373 patients were identified. ERCC1 C118T and C8092A could predict both ORR and OS for platinum-based chemotherapy in Asian NSCLC patients (CT + TT versus CC, ORR: OR = 0.80, 95% CI = 0.67–0.94; OS: HR = 1.24, 95% CI = 1.01–1.53) (CA + AA versus CC, ORR: OR = 0.76, 95% CI = 0.60–0.96; OS: HR = 1.37, 95% CI = 1.06–1.75).Conclusions. Current evidence strongly indicated the prospect of ERCC1 C118T and C8092A as predictive biomarkers for platinum-based chemotherapy in Asian NSCLC patients. However, the results should be interpreted with caution and large prospective studies are still required to further investigate these findings.

Download Full-text

Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients

PLoS ONE ◽

10.1371/journal.pone.0038150 ◽

2012 ◽

Vol 7 (6) ◽

pp. e38150 ◽

Cited By ~ 32

Author(s):

Ji-Ye Yin ◽

Qiong Huang ◽

Ying-Chun Zhao ◽

Hong-Hao Zhou ◽

Zhao-Qian Liu

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Meta Analysis ◽

Small Cell ◽

Small Cell Lung ◽

Platinum Based Chemotherapy ◽

Nsclc Patients

Download Full-text

PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis

Journal of Clinical Medicine ◽

10.3390/jcm10194583 ◽

2021 ◽

Vol 10 (19) ◽

pp. 4583

Author(s):

María Rosario García Campelo ◽

Edurne Arriola ◽

Begoña Campos Balea ◽

Marta López-Brea ◽

José Fuentes-Pradera ◽

...

Keyword(s):

Advanced Nsclc ◽

Meta Analysis ◽

Safety Data ◽

Phase Iii ◽

First Line ◽

Platinum Based Chemotherapy ◽

Significant Difference ◽

Safety Outcomes ◽

Using Data ◽

Nsclc Patients

This network meta-analysis (NMA) evaluates the safety of first-line programmed death-ligand 1 (PD-L1) inhibitor monotherapy in advanced NSCLC patients compared to platinum-based chemotherapy. We also compared the risk of adverse events (AEs) according to programmed cell death-1 receptor (PD-1) or PD-L1 inhibitors therapy. To that end, we conducted a series of metanalyses (MAs) using data from six phase III clinical trials, including 4053 patients. Our results show a reduced risk of any grade treatment-related AEs (risk ratio (RR) = 0.722 95% CI: 0.667–0.783, p = 0.002), and grade 3–5 AEs (RR = 0.406 95% CI: 0.340–0.485, p = 0.023) in immunotherapy as compared to chemotherapy. In contrast, a higher risk of immune-related AEs (irAEs) was estimated for immunotherapy versus chemotherapy. The subgroup MAs comparing PD-L1 to PD-1 inhibitors, determined a lower risk of AEs leading to treatment discontinuation in the anti-PD-L1 subgroup (RR = 0.47 95% CI: 0.29–0.75, p = 0.001); however, this statistically significant difference between anti-PD-L1 and anti-PD-1 subgroups was not reached for other safety outcomes analyzed. In conclusion, our findings show that PD-L1 inhibitor monotherapy improves safety outcomes in the 1L treatment of advanced NSCLC patients as compared to chemotherapy except for irAEs.

Download Full-text

Faculty Opinions recommendation of Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718052196.793482906 ◽

2013 ◽

Author(s):

Ian Beales

Keyword(s):

Gastric Adenocarcinoma ◽

Meta Analysis ◽

Line Treatment ◽

First Line ◽

Platinum Based Chemotherapy ◽

Advanced Gastric Adenocarcinoma ◽

First Line Treatment

Download Full-text

Serum interleukin-6 in schizophrenia: A system review and meta-analysis

Cytokine ◽

10.1016/j.cyto.2021.155441 ◽

2021 ◽

Vol 141 ◽

pp. 155441

Author(s):

Xin Zhou ◽

Bo Tian ◽

Hai-Bin Han

Keyword(s):

Interleukin 6 ◽

Meta Analysis ◽

System Review

Download Full-text

Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis

Scientific Reports ◽

10.1038/s41598-021-91234-y ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Hao Chen ◽

Hiromi Matsumoto ◽

Nobuyuki Horita ◽

Yu Hara ◽

Nobuaki Kobayashi ◽

...

Keyword(s):

Invasive Pneumococcal Disease ◽

Odds Ratio ◽

Pneumococcal Disease ◽

Web Of Science ◽

Meta Analysis ◽

Mortality Rates ◽

Solid Organ ◽

Factors Associated ◽

System Review ◽

Overall Mortality

AbstractRisk factors associated with mortality in invasive pneumococcal disease remain unclear. The present work is a meta-analysis of studies that enrolled only patients with invasive pneumococcal disease and reported on mortality. Potentially eligible reports were identified from PubMed, CHAHL, and Web of Science, comprising 26 reports in total. Overall mortality for invasive pneumococcal disease was reported as 20.8% (95% confidence interval (CI) 17.5–24%). Factors associated with mortality were age (odds ratio (OR) 3.04, 95% CI 2.5–3.68), nursing home (OR 1.62, 95% CI 1.13–2.32), nosocomial infection (OR 2.10, 95% CI 1.52–2.89), septic shock (OR 13.35, 95% CI 4.54–39.31), underlying chronic diseases (OR 2.34, 95% CI 1.78–3.09), solid organ tumor (OR 5.34, 95% CI 2.07–13.74), immunosuppressed status (OR 1.67, 95% CI 1.31–2.14), and alcohol abuse (OR 3.14, 95% CI 2.13–4.64). Mortality rates with invasive pneumococcal disease remained high, and these findings may help clinicians provide appropriate initial treatment for this disease.

Download Full-text

Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition

Investigational New Drugs ◽

10.1007/s10637-021-01143-0 ◽

2021 ◽

Author(s):

Julian Taugner ◽

Lukas Käsmann ◽

Monika Karin ◽

Chukwuka Eze ◽

Benedikt Flörsch ◽

...

Keyword(s):

Planning Target Volume ◽

Immune Checkpoint ◽

Target Volume ◽

Continuous Variable ◽

Stage Iii ◽

Checkpoint Inhibition ◽

Immune Checkpoint Inhibition ◽

Platinum Based Chemotherapy ◽

Stage Iii Nsclc ◽

Nsclc Patients

SummaryBackground. The present study evaluates outcome after chemoradiotherapy (CRT) with concurrent and/or sequential Programmed Cell Death 1 (PD-1) or Ligand 1 (PD-L1) immune checkpoint inhibition (CPI) for inoperable stage III NSCLC patients depending on planning target volume (PTV). Method and patients. Prospective data of thirty-three consecutive patients with inoperable stage III NSCLC treated with CRT and sequential durvalumab (67%, 22 patients) or concurrent and sequential nivolumab (33%, 11 patients) were analyzed. Different PTV cut offs and PTV as a continuous variable were evaluated for their association with progression-free (PFS), local–regional progression-free (LRPFS), extracranial distant metastasis-free (eMFS) and brain-metastasis free-survival (BMFS). Results. All patients were treated with conventionally fractionated thoracic radiotherapy (TRT); 93% to a total dose of at least 60 Gy, 97% of patients received two cycles of concurrent platinum-based chemotherapy. Median follow-up for the entire cohort was 19.9 (range: 6.0–42.4) months; median overall survival (OS), LRFS, BMFS and eMFS were not reached. Median PFS was 22.8 (95% CI: 10.7–34.8) months. Patients with PTV ≥ 900ccm had a significantly shorter PFS (6.9 vs 22.8 months, p = 0.020) and eMFS (8.1 months vs. not reached, p = 0.003). Furthermore, patients with PTV ≥ 900ccm and stage IIIC disease (UICC-TNM Classification 8th Edition) achieved a very poor outcome with a median PFS and eMFS of 3.6 vs 22.8 months (p < 0.001) and 3.6 months vs. not reached (p = 0.001), respectively. PTV as a continuous variable also had a significant impact on eMFS (p = 0.048). However, no significant association of different PTV cut-offs or PTV as a continuous variable with LRPFS and BMFS could be shown. The multivariate analysis that was performed for PTV ≥ 900ccm and age (≥ 65 years), gender (male), histology (non-ACC) as well as T- and N-stage (T4, N3) as covariates also revealed PTV ≥ 900ccm as the only factor that had a significant correlation with PFS (HR: 5.383 (95% CI:1.263–22.942, p = 0.023)). Conclusion. In this prospective analysis of inoperable stage III NSCLC patients treated with definitive CRT combined with concurrent and/or sequential CPI, significantly shorter PFS and eMFS were observed in patients with initial PTV ≥ 900ccm.

Download Full-text